hPSC-derived RPE transplantation for the treatment of macular degeneration

Qian Liu, Jun Liu, Akon Higuchi

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

1 Scopus citations

Abstract

Macular degeneration (MD) is a group of diseases characterized by irreversible and progressive vision loss. Patients with MD suffer from severely impaired central vision, especially elderly people. Currently, only one type of MD, wet age-related macular degeneration (AMD), can be treated with anti-vascular endothelium growth factor (VEGF) drugs. Other types of MD remain difficult to treat. With the advent of human pluripotent stem cells (hPSCs) and their differentiation into retinal pigmented epithelium (RPE), it is promising to treat patients with MD by transplantation of hPSC-derived RPE into the subretinal space. In this review, the current progress in hPSC-derived RPE transplantation for the treatment of patients with MD is described from bench to bedside, including hPSC differentiation into RPE and the characterization and usage of hPSC-derived RPE for transplantation into patients with MD.

Original languageEnglish
Title of host publicationProgress in Molecular Biology and Translational Science
EditorsAkon Higuchi, Yinghong Zhou, Shih-Hwa Chiou
PublisherElsevier B.V.
Pages227-269
Number of pages43
ISBN (Print)9780443134111
DOIs
StatePublished - Jan 2023

Publication series

NameProgress in Molecular Biology and Translational Science
Volume199
ISSN (Print)1877-1173
ISSN (Electronic)1878-0814

Keywords

  • Human pluripotent stem cells
  • Macular degeneration
  • Retinal pigmented epithelium
  • Stem cell therapy

Fingerprint

Dive into the research topics of 'hPSC-derived RPE transplantation for the treatment of macular degeneration'. Together they form a unique fingerprint.

Cite this